PMID- 27343723
OWN - NLM
STAT- MEDLINE
DCOM- 20170720
LR  - 20191210
IS  - 1872-7905 (Electronic)
IS  - 0022-1759 (Linking)
VI  - 436
DP  - 2016 Sep
TI  - A novel immunoassay for quantitative drug abuse screening in serum.
PG  - 34-40
LID - S0022-1759(16)30119-3 [pii]
LID - 10.1016/j.jim.2016.06.004 [doi]
AB  - An immunoassay was established which enables a reliable quantification of 
      serological drug samples. The assay is based on a competitive ELISA. In total 
      nine drugs (amphetamine, methamphetamine, 3,4-methylenedioxy-methamphetamine 
      (MDMA), tetrahydrocannabinol (THC), phencyclidine (PCP), methadone, morphine, 
      cocaine and benzoylecgonine) were tested. All reagents had to pass through a 
      stringent validation process. Within the established test for three out of the 
      nine drugs no cross-reactivity with any tested compounds, e.g. serum, other 
      antibodies or chemically related molecules was detectable for the tested 
      antibodies. Furthermore, a sensitive and selective detection was possible, even 
      in the presence of up to 9 drugs or of various anti-drug antibodies. After 
      exclusion of cross-reactivities antibodies against three drugs (methadone, MDMA, 
      benzoylecgonine) were validated, which allowed a specific and sensitive 
      quantification. For the competitive measurements CVs in the range of 2-17% could 
      be reached with LLOQs of 10ng/mL and LODs of 150ng/mL for methadone, 250ng/mL for 
      MDMA and 400ng/mL for benzoylecgonine. Anonymized serum samples (n=10) provided 
      by the office of criminal investigation Berlin were analyzed for verification 
      purposes. Evaluation of these data showed a correlation (CV) of  approximately 0.9 with 
      standard GC-MS methods. A miniaturization on microarray was possible by using the 
      anti-MDMA antibody for the detection of MDMA in serum. The microarray increased 
      the through-put drastically and enabled the simultaneous quantification of 
      various drugs.
CI  - Copyright (c) 2016. Published by Elsevier B.V.
FAU - Schumacher, Sarah
AU  - Schumacher S
AD  - Fraunhofer Institute for Cell Therapy and Immunology, Bioanalytics und 
      Bioprocesses, Am Muhlenberg 13, 14476 Potsdam, Germany; Humboldt University 
      Berlin, Department of Biology, Invalidenstr. 110, 10115 Berlin, Germany.
FAU - Seitz, Harald
AU  - Seitz H
AD  - Fraunhofer Institute for Cell Therapy and Immunology, Bioanalytics und 
      Bioprocesses, Am Muhlenberg 13, 14476 Potsdam, Germany. Electronic address: 
      harald.seitz@izi-bb.fraunhofer.de.
LA  - eng
PT  - Journal Article
PT  - Validation Study
DEP - 20160623
PL  - Netherlands
TA  - J Immunol Methods
JT  - Journal of immunological methods
JID - 1305440
RN  - 0 (Illicit Drugs)
SB  - IM
MH  - Enzyme-Linked Immunosorbent Assay/*methods
MH  - Gas Chromatography-Mass Spectrometry
MH  - Humans
MH  - Illicit Drugs/*blood/classification
MH  - Microarray Analysis/*methods
MH  - Regression Analysis
MH  - Substance Abuse Detection/*methods
OTO - NOTNLM
OT  - Drug Abuse
OT  - Immunoassay
OT  - Multiplex
OT  - Serum
OT  - Validation
EDAT- 2016/06/28 06:00
MHDA- 2017/07/21 06:00
CRDT- 2016/06/26 06:00
PHST- 2016/03/07 00:00 [received]
PHST- 2016/06/21 00:00 [revised]
PHST- 2016/06/21 00:00 [accepted]
PHST- 2016/06/26 06:00 [entrez]
PHST- 2016/06/28 06:00 [pubmed]
PHST- 2017/07/21 06:00 [medline]
AID - S0022-1759(16)30119-3 [pii]
AID - 10.1016/j.jim.2016.06.004 [doi]
PST - ppublish
SO  - J Immunol Methods. 2016 Sep;436:34-40. doi: 10.1016/j.jim.2016.06.004. Epub 2016 
      Jun 23.